|Day Low/High||0.68 / 0.72|
|52 Wk Low/High||0.60 / 4.46|
The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
Acorda Therapeutics announced positive results in a clinical trial for its drug CVT-301.
Ron Cohen, CEO of Acorda Therapeutics, says his company's pipeline is full and he is less worried about Obamacare than the FDA.